Recurrent vulvovaginal candidiasis.
Recurrent vulvovaginal candidiasis affects five percent of women of child-bearing age. The most common organism is Candidia albicans, but an increasing number of infections are caused by nonalbicans species. Fungal culture directs treatment as nonalbicans species may be azole resistant. C. albicans will respond to anyazole antifungal. Treat C. glabrata with boric acid. Maintenance therapy should be started immediately after treatment of the acute episode and should last for six months.
Ringdahl
Erika N
EN
Department of Family and Community Medicine, University of Missouri, Columbia, USA.
D000208:Acute Disease; D000935:Antifungal Agents / Q000627:therapeutic use*; D001888:Boric Acids / Q000627:therapeutic use; D002176:Candida albicans / Q000187:drug effects; D041221:Candida glabrata / Q000187:drug effects; D002181:Candidiasis, Vulvovaginal / Q000175:diagnosis / Q000188:drug therapy / Q000517:prevention & control*; D017050:Episode of Care; D005260:Female; D006801:Humans; D007654:Ketoconazole / Q000627:therapeutic use; D055502:Secondary Prevention
D000935:Antifungal Agents; D001888:Boric Acids; C032688:boric acid; D007654:Ketoconazole